Tubeimoside I induces autophagy in HepG2 cells by activating the AMP‑activated protein kinase signaling pathway
- Chengxu Ruan
- Lijuan You
- Yingdong Qiu
- Xiao Cui
- Defeng Wu
Affiliations: College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350116, P.R. China, College of Bee Science, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China
- Published online on: May 13, 2020 https://doi.org/10.3892/ol.2020.11604
Copyright: © Ruan
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Tubeimoside I (TBMS) is a natural compound with antitumor properties. However, the detailed mechanism underlying the function of TBMS in liver cancer has not been fully elucidated. In the present study, TBMS was shown to suppress cell proliferation and induce S phase cell cycle arrest in HepG2 cells. Furthermore, TBMS treatment induced autophagy, evidenced by autophagosome accumulation, and increased the mRNA expression of Beclin 1 and microtubule‑associated protein 1 light chain 3 (LC3)‑I. However, flow cytometry analysis demonstrated that TBMS exerted no effect on cell apoptosis. Moreover, TBMS increased the phosphorylation of AMP‑activated protein kinase (AMPK) in a concentration‑dependent manner, thereby activating the AMPK signaling pathway. A specific AMPK inhibitor, compound C (CC), caused markedly suppressed TBMS‑induced accumulation of LC3‑II. In addition, the mRNA expression of LC3‑Ι and Beclin 1 was also suppressed in cells treated with TBMS and CC in combination. The results of the present study provide new insights into the role of TBMS in inducing autophagy and support the potential application of TBMS for liver cancer treatment in the clinical setting.